Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.

Immunome, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

BOTHELL, WASH.--(BUSINESS WIRE)--IMMUNOME, INC. (THE COMPANY) (NASDAQ: IMNM), A CLINICAL-STAGE TARGET ONCOLOGY COMPANY FOCUSED ON DEVELOPING FIRST-IN-CLASS AND BEST-IN-CLASS TARGETED CANCER THERAPIES, ANNOUNCED TODAY THAT ON SEPTEMBER 1, 2026, THE COMPENSATION COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS (THE COMPENSATION COMMITTEE) GRANTED INDUCEMENT AWARDS CONSISTING OF NON-STATUTORY STOCK OPTIONS TO PURCHASE AN AGGREGATE OF 86,500 SHARES OF COMMON STOCK TO FOUR NEW EMPLOYEES UNDER THE CO.

IMMUNOME REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

BOTHELL, WASH.--(BUSINESS WIRE)--IMMUNOME, INC. (NASDAQ: IMNM), A CLINICAL-STAGE TARGETED ONCOLOGY COMPANY FOCUSED ON DEVELOPING FIRST-IN-CLASS AND BEST-IN-CLASS TARGETED CANCER THERAPIES, TODAY ANNOUNCED THAT IMMUNOME MANAGEMENT WILL PRESENT AT H.C. WAINWRIGHT'S 28TH ANNUAL GLOBAL INVESTMENT CONFERENCE ON SEPTEMBER 14, 2026, AT 11:00 A.M. ET.INTERESTED PARTIES CAN ACCESS THE LIVE AUDIO WEBCAST OF THE PRESENTATION FROM THE INVESTOR RELATIONS SECTION OF THE COMPANY'S WEBSITE AT WWW.IMMUNOME.COM.

IMMUNOME TO PRESENT AT THE H.C. WAINWRIGHT 28TH ANNUAL GLOBAL INVESTMENT CONFERENCE

STUDY MET PRIMARY ENDPOINT OF MEAN TOTAL IMPROVEMENT SCORE (TIS) AT WEEK 52 IN THE COMBINED STUDY POPULATION OF IMNM AND DM PATIENTS (P=0.0011) PATIENT IMPROVEMENTS OBSERVED EARLY AND SUSTAINED THROUGHOUT STUDY; CONSISTENT TREATMENT EFFECT ACROSS IMNM AND DM FIRST PHASE 3 STUDY TO SHOW STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENTS IN DISEASE ACTIVITY INIMNM, A SUBTYPE WITH NO APPROVED THERAPY ARGENX TO HOST A CONFERENCE CALL ON AUGUST 17 TH AT 2:30 PM CET/ 8:30 AM ET AUGUST 17, 2026, 7:00 AM CET AMSTERDAM, THE NETHERLANDS  ARGENX SE (EURONEXT & NASDAQ: ARGX), A GLOBAL IMMUNOLOGYINNOVATIONCOMPANY, TODAY ANNOUNCED POSITIVE TOPLINE RESULTS FROM THE ALKIVIA PHASE 3 STUDY EVALUATING VYVGART HYTRULO (EFGARTIGIMOD ALFA AND HYALURONIDASE-QVFC) IN ADULTS WITH AUTOIMMUNE MYOSITIS. STUDY MET ITS PRIMARY ENDPOINT (P=0.0011) IN THE COMBINED IMMUNE-MEDIATED NECROTIZING MYOPATHY (IMNM) AND DERMATOMYOSITIS (DM) POPULATION, PATIENTS TREATED WITH EFGARTIGIMOD DEMONSTRATED STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL 15.4-POINT GREATER IMPROVEMENT IN MEAN TOTAL IMPROVEMENT SCORE (TIS) AT WEEK 52 VERSUS PLACEBO (47.95 VS 32.56).

ARGENX ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3 ALKIVIA TRIAL OF EFGARTIGIMOD IN AUTOIMMUNE MYOSITIS

BOTHELL, WASH.--(BUSINESS WIRE)--IMMUNOME, INC. (NASDAQ: IMNM), A BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING FIRST-IN-CLASS AND BEST-IN-CLASS TARGETED CANCER THERAPIES, TODAY ANNOUNCED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026, AND PROVIDED A BUSINESS UPDATE. WE CONTINUE TO EXECUTE AGAINST OUR STRATEGY OF BUILDING A DIVERSIFIED TARGETED ONCOLOGY COMPANY WITH MULTIPLE OPPORTUNITIES TO BRING NEEDED THERAPIES TO PATIENTS, SAID CLAY B. SIEGALL, PH.D., PRESIDENT AND CHIEF EXECUTIVE OF.

IMMUNOME REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BOTHELL, WASH.--(BUSINESS WIRE)--IMMUNOME, INC. (THE COMPANY) (NASDAQ: IMNM), A BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING FIRST-IN-CLASS AND BEST-IN-CLASS TARGETED CANCER THERAPIES, ANNOUNCED TODAY THAT ON AUGUST 3, 2026, THE COMPENSATION COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS (THE COMPENSATION COMMITTEE) GRANTED INDUCEMENT AWARDS CONSISTING OF NON-STATUTORY STOCK OPTIONS TO PURCHASE AN AGGREGATE OF 176,500 SHARES OF COMMON STOCK TO NINE NEW EMPLOYEES UNDER THE COMPANY'S 2024 INDUC.

BOTHELL, WASH.--(BUSINESS WIRE)--IMMUNOME, INC. (NASDAQ: IMNM), A BIOTECHNOLOGY COMPANY COMMITTED TO DEVELOPING FIRST-IN-CLASS AND BEST-IN-CLASS TARGETED CANCER THERAPIES, TODAY ANNOUNCED THAT THE FIRST PATIENT HAS BEEN DOSED IN THE PHASE 1, FIRST-IN-HUMAN TRIAL OF IM-3050, AN INVESTIGATIONAL FAP-TARGETED RADIOLIGAND THERAPY BEING EVALUATED IN PATIENTS WITH FAP-EXPRESSING ADVANCED SOLID TUMORS.FAP IS A HIGH-POTENTIAL TARGET WITH EXPRESSION IN 75% OF SOLID TUMORS, SAID BOB LECHLEIDER, M.D., CHI.

IMMUNOME ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 TRIAL EVALUATING IM-3050, AN FAP-TARGETED RADIOLIGAND THERAPY, IN PATIENTS WITH FAP-EXPRESSING ADVANCED SOLID TUMORS

BOTHELL, WASH.--(BUSINESS WIRE)--IMMUNOME, INC. (NASDAQ: IMNM), A BIOTECHNOLOGY COMPANY COMMITTED TO DEVELOPING FIRST-IN-CLASS AND BEST-IN-CLASS TARGETED CANCER THERAPIES, TODAY ANNOUNCED THE U.S. FOOD AND DRUG ADMINISTRATION (FDA OR THE AGENCY) HAS ACCEPTED ITS NEW DRUG APPLICATION (NDA) FOR VAREGACESTAT, AN INVESTIGATIONAL, ORAL, ONCE-DAILY GAMMA SECRETASE INHIBITOR (GSI), FOR THE TREATMENT OF ADULTS WITH DESMOID TUMORS. THE FDA ASSIGNED A PRESCRIPTION DRUG USER FEE ACT (PDUFA) TARGET ACTION.

IMMUNOME ANNOUNCES U.S. FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR VAREGACESTAT FOR THE TREATMENT OF ADULTS WITH DESMOID TUMORS

BOTHELL, WASH.--(BUSINESS WIRE)--IMMUNOME, INC. (THE COMPANY) (NASDAQ: IMNM), A BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING FIRST-IN-CLASS AND BEST-IN-CLASS TARGETED CANCER THERAPIES, ANNOUNCED TODAY THAT ON JULY 1, 2026, THE COMPENSATION COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS (THE COMPENSATION COMMITTEE) GRANTED INDUCEMENT AWARDS CONSISTING OF NON-STATUTORY STOCK OPTIONS TO PURCHASE AN AGGREGATE OF 344,000 SHARES OF COMMON STOCK TO SEVENTEEN NEW EMPLOYEES UNDER THE COMPANY'S 2024 IN.

BOTHELL, WASH.--(BUSINESS WIRE)--IMMUNOME, INC. (NASDAQ: IMNM), A BIOTECHNOLOGY COMPANY COMMITTED TO DEVELOPING FIRST-IN-CLASS AND BEST-IN-CLASS TARGETED CANCER THERAPIES, TODAY ANNOUNCED THAT THE FIRST PATIENT HAS BEEN DOSED IN THE PHASE 1, FIRST-IN-HUMAN TRIAL OF IM-1617, A POTENTIAL FIRST-IN-CLASS ADC DIRECTED AT AN UNDISCLOSED SOLID TUMOR TARGET AND INCORPORATING HC74, IMMUNOME'S PROPRIETARY TOP1 INHIBITOR PAYLOAD. THE FIRST PATIENT DOSED WITH IM-1617 IS A SIGNIFICANT MILESTONE FOR IMMUNOM.

IMMUNOME ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 TRIAL EVALUATING IM-1617, A POTENTIAL FIRST-IN-CLASS ADC, IN PATIENTS WITH ADVANCED SOLID TUMORS

BOTHELL, WASH.--(BUSINESS WIRE)--IMMUNOME, INC. (THE COMPANY) (NASDAQ: IMNM), A BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING FIRST-IN-CLASS AND BEST-IN-CLASS TARGETED CANCER THERAPIES, ANNOUNCED TODAY THAT ON JUNE 1, 2026, THE COMPENSATION COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS (THE COMPENSATION COMMITTEE) GRANTED INDUCEMENT AWARDS CONSISTING OF NON-STATUTORY STOCK OPTIONS TO PURCHASE AN AGGREGATE OF 353,000 SHARES OF COMMON STOCK TO TWENTY NEW EMPLOYEES UNDER THE COMPANY'S 2024 INDUC.

BOTHELL, WASH.--(BUSINESS WIRE)--IMMUNOME, INC. (NASDAQ: IMNM), A BIOTECHNOLOGY COMPANY COMMITTED TO DEVELOPING FIRST-IN-CLASS AND BEST-IN-CLASS TARGETED CANCER THERAPIES, TODAY ANNOUNCED DETAILED EFFICACY AND SAFETY RESULTS FROM RINGSIDE, THE GLOBAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL OF VAREGACESTAT IN PATIENTS WITH PROGRESSING DESMOID TUMORS. THE DATA ARE BEING PRESENTED TODAY IN AN ORAL ABSTRACT SESSION AT THE 2026 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL.

Immunome, Inc.

IMNM

Price

Financial Reports

No items found.

Press Releases

Immunome, Inc.

IMNM.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

IMNM